Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost
- PMID: 17164574
- DOI: 10.1159/000097903
Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost
Abstract
Purpose: To compare the 24-hour efficacy of dorzolamide and timolol maleate administered twice daily to primary open-angle glaucoma patients whose intraocular pressure (IOP) could not be adequately controlled with latanoprost monotherapy.
Methods: In this double-blind prospective crossover clinical comparison trial, 36 primary open-angle glaucoma patients with uncontrolled IOP despite treatment with latanoprost applied once daily were administered timolol and dorzolamide twice daily. The treatment sequence was randomized. All patients underwent measurements for four 24-hour tonometric curves: at baseline and after each 4-week period of treatment. The IOP measurements were taken at 06:00, 09:00, 12:00, 15:00, 18:00, 21:00, 24:00 and 03:00 h. The between-group differences were tested for significance by means of parametric analysis of variance at each time point and circadian curve. The peak values within circadian curve were defined. The mean of the exact amount and percentage of additional IOP reductions from baseline were evaluated and success rates (a minimum of 10% reduction) were determined for both drug regimens.
Results: The mean peak/circadian curve IOPs were 23.4 +/- 2.2/21.8 +/- 2.2 mm Hg at dorzolamide baseline, 23.3 +/- 2.2/21.7 +/- 2.1 mm Hg at timolol baseline, and reduced to 20.2 +/- 1.7/18.7 +/- 1.7 mm Hg and 20.7 +/- 2.4/19.4 +/- 1.6 mm Hg, respectively. When added to latanoprost, both dorzolamide and timolol lowered IOP at circadian curve significantly (p < 0.05). Dorzolamide reduced baseline IOP values at each time point. Timolol also significantly reduced baseline IOP values at all time points except at 03:00. The mean of the exact amount and percentage of reduction in IOP at circadian curve and 5 out of 8 time points were significantly greater with dorzolamide add-on treatment (p < 0.05). The successful reduction rates were 86% for the dorzolamide group and 61% for the timolol group (p = 0.016; chi(2) test).
Conclusion: Both of the combinations are effective in lowering IOP, the exact amount and percentage of reduction is greater with the latanoprost + dorzolamide regimen, especially at night-time.
Similar articles
-
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566-73. Invest Ophthalmol Vis Sci. 2000. PMID: 10937568 Clinical Trial.
-
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.J Glaucoma. 2010 Jun-Jul;19(5):331-5. doi: 10.1097/IJG.0b013e3181b4cab4. J Glaucoma. 2010. PMID: 19730119 Clinical Trial.
-
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.Ophthalmology. 2008 Jul;115(7):1117-1122.e1. doi: 10.1016/j.ophtha.2007.10.004. Epub 2008 Feb 20. Ophthalmology. 2008. PMID: 18082886
-
The effect of latanoprost on circadian intraocular pressure.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S90-6. doi: 10.1016/s0039-6257(02)00296-5. Surv Ophthalmol. 2002. PMID: 12204704 Review.
-
Latanoprost versus combined timolol and dorzolamide.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S148-54. doi: 10.1016/s0039-6257(02)00290-4. Surv Ophthalmol. 2002. PMID: 12204712 Review.
Cited by
-
Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients.Clin Ophthalmol. 2009;3:493-500. doi: 10.2147/opth.s6764. Epub 2009 Sep 7. Clin Ophthalmol. 2009. PMID: 19750124 Free PMC article.
-
Pharmacological management of primary open-angle glaucoma: second-line options and beyond.Drugs Aging. 2008;25(9):729-59. doi: 10.2165/00002512-200825090-00002. Drugs Aging. 2008. PMID: 18729546 Review.
-
Twenty-Four-Hour Variation of Intraocular Pressure in Primary Open-Angle Glaucoma Treated with Triple Eye Drops.J Ophthalmol. 2017;2017:4398494. doi: 10.1155/2017/4398494. Epub 2017 May 3. J Ophthalmol. 2017. PMID: 28553549 Free PMC article.
-
Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months.Clin Ophthalmol. 2011;5:393-6. doi: 10.2147/OPTH.S17527. Epub 2011 Mar 22. Clin Ophthalmol. 2011. PMID: 21499562 Free PMC article.
-
24-h Efficacy of Glaucoma Treatment Options.Adv Ther. 2016 Apr;33(4):481-517. doi: 10.1007/s12325-016-0302-0. Epub 2016 Feb 24. Adv Ther. 2016. PMID: 26909513 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical